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pathogenesis of PAH and serotonin can increase CYP1B1 expression in human
pulmonary arterial smooth muscle cells (hPASMCs).  We hypothesized that an
increase in intracellular serotonin via increased SERT expression may dysregulate
estrogen metabolism via CYP1B1 to facilitate PAH. Consistent with this hypothesis, we
found elevated lung CYP1B1 protein expression in female SERT+ mice accompanied
by PH, which was attenuated by the CYP1B1 inhibitor, 2,3',4,5'-tetramethoxystilbene
(TMS). Lungs from female SERT+ mice demonstrated an increase in oxidative stress
which was marked by the expression of 8-hydroxyguanosine; however this was
unaffected by CYP1B1 inhibition. SERT expression was increased in monocrotaline-
induced PH in female rats; however, TMS did not reverse PH in monocrotaline-treated
rats, but prolonged survival. Stimulation of hPASMCs with the CYP1B1 metabolite 16α-
hydroxyestrone increased cellular proliferation, which was attenuated by an inhibitor of
estrogen receptor alpha (ERα; MPP) and a specific ERα antibody. Thus, increased
intracellular serotonin caused by increased SERT expression may contribute to PAH
pathobiology by dysregulation of estrogen metabolic pathways via increased CYP1B1
activity. This promotes PASMC proliferation by the formation of pathogenic metabolites
of estrogen that mediate their effects via ERα. Our studies indicate that targeting this
pathway in PAH may provide a promising anti-proliferative therapeutic strategy.
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Abstract 
Pulmonary arterial hypertension (PAH) is a devastating vasculopathy that 
predominates in women and has been associated with dysregulated estrogen and serotonin 
signalling. Over-expression of the serotonin transporter (SERT+) in mice results in an 
estrogen-dependent development of pulmonary hypertension (PH). Estrogen metabolism by 
cytochrome P450 1B1 (CYP1B1) contributes to the pathogenesis of PAH and serotonin can 
increase CYP1B1 expression in human pulmonary arterial smooth muscle cells (hPASMCs).  
We hypothesized that an increase in intracellular serotonin via increased SERT expression 
may dysregulate estrogen metabolism via CYP1B1 to facilitate PAH. Consistent with this 
hypothesis, we found elevated lung CYP1B1 protein expression in female SERT+ mice 
accompanied by PH, which was attenuated by the CYP1B1 inhibitor, 2,3',4,5'-
tetramethoxystilbene (TMS). Lungs from female SERT+ mice demonstrated an increase in 
oxidative stress which was marked by the expression of 8-hydroxyguanosine; however this 
was unaffected by CYP1B1 inhibition. SERT expression was increased in monocrotaline-
induced PH in female rats; however, TMS did not reverse PH in monocrotaline-treated rats, 
but prolonged survival. Stimulation of hPASMCs with the CYP1B1 metabolite 16α-
hydroxyestrone increased cellular proliferation, which was attenuated by an inhibitor of 
estrogen receptor alpha (ERα; MPP) and a specific ERα antibody. Thus, increased 
intracellular serotonin caused by increased SERT expression may contribute to PAH 
pathobiology by dysregulation of estrogen metabolic pathways via increased CYP1B1 
activity. This promotes PASMC proliferation by the formation of pathogenic metabolites of 
estrogen that mediate their effects via ERα. Our studies indicate that targeting this pathway in 
PAH may provide a promising anti-proliferative therapeutic strategy. 
248 words
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Introduction 
Pulmonary arterial hypertension (PAH) is a fatal cardiovascular disorder with a 
poorly understood aetiology. It is characterised by obliteration of the small and medium 
pulmonary arteries resulting in increased pulmonary pressures and subsequent enlargement 
and failure of the right ventricle. Female sex is possibly the strongest and most established 
risk factor for PAH, with more than 70% of patients diagnosed being female1-3. 17β-estradiol 
(estrogen) is recognized as a pathogenic mediator in numerous diseases either through 
aberrant estrogen receptor (ER) mediated signalling and/or metabolism4. More recently, 
increasing evidence suggests that PAH may also be affected by abnormal activity of the 
estrogen pathway to adversely affect pulmonary vascular cell homeostasis5-12. It was initially 
hypothesized that estrogens and/or their metabolites may promote disease development and 
progression. However, in the ‘classical’ animal models of PAH (monocrotaline (MCT) and 
hypoxia), exogenous administration of estrogen was shown to have a beneficial effect, by in 
part, promoting cardiac function13-16. This is in line with the extensive literature that reports 
cardio-protective effects of estrogens17. More recently, we have provided compelling 
evidence that the endogenous synthesis of estrogen within the pulmonary arteries by the 
cytochrome P450 (CYP) enzyme aromatase, promotes the development of pulmonary 
hypertension (PH) in female rodents6,12. 
One criticism of utilizing the ‘classical’ animal models of PAH to study the effects of 
gender is that they do not recreate the gender disparity that is observed in clinic. We have 
recently described several novel murine models of PH that are specific to female mice. These 
include SERT+ mice13, mice that over-express the S100A4 calcium binding protein18 (which 
requires co-operation between the 5-HT1B receptor and SERT19) and mice administered with 
dexfenfluramine (an indirect serotinergic agonist)20.  Ovariectomy was shown to reverse PH 
in these mice confirming a role for sex hormones in these female specific models13,18,20. Of 
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interest, these models all depend upon up-regulation of the serotinergic pathway, suggesting 
interplay of the serotonin and estrogen pathways in disease development.  
The metabolic fate of estrogen is regulated by the activity of CYP enzymes to yield 
biologically active metabolites21. We have previously shown that at least one CYP, CYP1B1, 
is highly expressed within the pulmonary arterial lesions of patients with PAH, whilst 
minimal expression is observed in patients without any reported evidence of PAH5. CYP1B1 
metabolizes estrogen primarily to the 4-hydroxylated estrogens and to a lesser extent to the 2- 
and the 16α-hydroxylated estrogens (amongst others)22-24. CYP1B1 polymorphisms that 
result in a reduced 2-OHE1/16α-OHE1 estrogen metabolite ratio have been reported in 
patients with PAH associated with mutations in the bone morphogenic protein receptor type 
II (BMPR2) 7– the predominant genetic basis for the development of heritable PAH25. 
Importantly, inhibition of estrogen metabolism by CYP1B1 can attenuate the development of 
experimental PH induced by hypoxia-, SU5416+hypoxia5 and dexfenfluramine20.  
Pulmonary arterial smooth muscle cell (PASMC) proliferation is an established and 
dominant feature associated with PAH pathobiology26,27. Estrogen induces proliferation of 
PASMCs and this is attenuated by CYP1B1 inhibition5. CYP1B1 expression is increased in 
PASMCs isolated from patients with idiopathic PAH and in female mice that overexpress 
SERT28 and serotonin can increase the expression of CYP1B1 in healthy PASMCs28. We 
therefore hypothesized that CYP1B1 may play a causative role in the development of PH in 
female SERT+ mice by promoting pathologic estrogen metabolism. To test this hypothesis, 
we assessed the therapeutic potential of CYP1B1 inhibition in female SERT+ mice. We also 
tested this in the MCT model of PAH which has elevated SERT expression29 and examined 
the molecular mechanisms that may mediate the pathogenic signalling associated with 
elevated CYP1B1.  
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Methods 
Ethics 
All experimental procedures were carried out in accordance with the United Kingdom 
Animal Procedures Act (1986) and with the "Guide for the Care and Use of Laboratory 
Animals" published by the US National Institutes of Health (NIH publication No. 85-23, 
revised 1996). Rodents were housed in a 12-hour light dark cycle with access to food and 
water ad libitum. Experimental procedures using hPASMCs conform to the principles 
outlined in the Declaration of Helsinki. All animals were randomly allocated to groups and 
all measurements and analysis were done in a blinded fashion, where possible. 
Animal models and In Vivo CYP1B1 inhibition with 2,3’,4,5’-Tetramethoxystilbene 
5-6 month-old female mice ubiquitously overexpressing the human SERT gene 
(SERT+ mice) were generated as previously described on a C57Bl/6J CBA background30. 
These were a kind gift from the late Professor Tony Harmar (University of Edinburgh). Age-
matched littermates (here-after referred to as wild-type) were studied as controls. Mice were 
subdivided into groups to receive either the highly potent and selective CYP1B1 inhibitor, 
2,3’,4,5’-Tetramethoxystilbene (TMS; 1.5mg/kg/day by intra peritoneal (i.p.) injection; 
Tocris Biosciences, UK) or vehicle (~5% (v/v) ethanol in 0.9% saline) for 14 days prior to 
assessment of hemodynamic parameters.  
Male and female Wistar rats (Harlan Laboratories, Oxon, UK), 10-12 weeks old at 
termination procedure received either the pneumotoxin MCT pyrrole (Sigma-Aldrich, Dorset, 
UK) or its vehicle at a dose of 60mg/kg by subcutaneous (s.c.) injection in the flank of the rat 
at day 0. MCT was dissolved in 1mol/L hydrogen chloride (HCl) at a concentration of 100 
mg/mL, neutralized with 1mol/L sodium hydroxide (NaOH) and diluted with sterile distilled 
water to 6 mg/mL. All animals were weighed every day and monitored for any signs of 
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discomfort. One single injection of MCT is sufficient to induce a PH phenotype in rats (MCT 
does not induce PH in mice). MCT mediates damage to the pulmonary endothelium and 
promotes the extension of smooth muscle cells into normally non-muscular pulmonary 
arteries promoting PH and right ventricular heart failure 31. 14 days post MCT injection 
animals were administered with the CYP1B1 inhibitor TMS at 3mg/kg/day or its vehicle 
(~5% (v/v) ethanol in 0.9% saline) by i.p. injection for an additional 14 days prior to 
hemodynamic analysis. 
In vivo hemodynamic measurements 
Rats and mice were anaesthetized with isoflurane supplemented with a constant flow 
of oxygen. Right ventricular systolic pressures (RVSP) were obtained by transdiaphragmatic 
puncture of the right ventricle with a saline-filled 25-gauge needle (in mice) and by jugular 
vein cannulation of the right ventricle using a fluid-filled catheter (in rats). To monitor off-
target effects on the systemic vasculature, mean systemic arterial pressures (SAP) were 
monitored by micro-cannulation of the left common carotid artery. 
Right ventricular hypertrophy 
RV hypertrophy was assessed by the Fulton Index32 by expressing the dry weight of 
the right ventricle over the dry weight of the left ventricle + septum.  
Lung histopathology 
The inferior lobe of the lung was fixed in 10% neutral buffered formalin for a 
minimum of 4 hours with gentle agitation prior to embedding in paraffin. 3μm sections were 
cut and stained using elastin and counterstained with Picro Sirius Red for identification of 
vascular thickening in the small arteries with an internal diameter up to 80µm. This was 
characterized by an increase in the vessel wall diameter in more than 50% of the arterial wall. 
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The total number of remodeled vessels was expressed over the total number of vessels 
present within a lung section.  
CYP1B1 immunolocalization 
CYP1B1 immunolocalization was determined in mouse and rat pulmonary arteries by 
immunohistochemistry, as described previously5. Briefly, 3μm sections were deparaffinised 
and rehydrated through a xylene-ethanol gradient to water. After antigen retrieval with citric 
acid buffer, endogenous peroxidase and biotin activity was blocked followed by a 1 hour 
incubation with 2.5% normal horse serum to block non-specific binding. Sections were 
incubated overnight at 4°C with an antibody against CYP1B1 (0.6μg/mL, ab32649, Abcam, 
UK), proliferating cell nuclear antigen (PCNA; 0.2μg/mL, ab2426, Abcam), SERT (1:200, 
whole antiserum, ab44520, Abcam) or α-smooth muscle cell actin (α-SMA; 0.4μg/mL, 
ab5694, Abcam). Excess primary antibody was removed by 3 consecutive washes in TBS-T 
and then incubated with a secondary anti-rabbit antibody for 1 hour at room temperature. 
Cells positive for CYP1B1 were visualized by VIP (which stains pink; Vector Laboratories, 
UK) in mice and DAB (which stains dark brown; Vector Laboratories) in rats and humans. 
Cells positive for PCNA and α-SMA were visualized by DAB. Rat sections were 
counterstained with hematoxylin. Images were captured using a Zeiss Axio Imager M1. For 
all antibodies, an IgG control was performed at the same concentration to control for non-
specific binding.  
PCNA Quantification 
The percentage of PCNA expressing nuclei was calculated using a free web 
application (ImmunoRatio) used for automated analysis of immunostained tissue sections. 
The application segments diaminobenzidine-stained (DAB) and hematoxylin-stained nuclei 
regions from the user-submitted image and calculates the percentage of DAB-stained nuclear 
area over total nuclear area. A total of 3-4 pulmonary arteries were analysed per lung section. 
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Determination of reactive oxygen species in lung sections by immunofluorescence 
 Immunohistochemistry of the reactive oxygen species (ROS) marker, 8-
hydroxyguanosine (8-OHG) was determined in the lungs of wild-type, SERT+ and SERT+ 
TMS treated mice. Sections were deparaffinised in a xylene-ethanol to water gradient. 
Antigen retrieval was performed by boiling slides in EDTA (pH 8.0) for 15 min prior to a 1 
hour incubation in a humidified chamber at room temperature with 10% donkey serum/1% 
BSA in 1xTBS-T to block non-specific binding. Sections were incubated with an antibody 
against 8-OHG overnight at 4°C (5g/mL, ab10802, Abcam). For identification of 8-OHG 
positive cells, sections were incubated with Alexa-fluor-488-conjugated donkey anti-goat 
secondary antibody (Molecular probes, A-11055, Life Technologies, UK) for 45 mins at 
room temperature in the dark. Lipofuscin-mediated auto-fluorescence was removed using 
0.1% Sudan Black B (Sigma-Aldrich, UK) in methanol w/v for 10 mins. Slides were 
mounted using ProLong Gold anti-fade mounting media containing DAPI (Molecular probes, 
P-36931, Life technologies, UK). Fluorescence imaging was measured in an Axiovert 200M 
microscope with a laser-scanning module LSM 510 (Carl Zeiss AG, Germany). DAPI was 
excited at 405 nm and Alexa-fluor 488 at 488 nm. Images were captured using the LSM 510 
evaluation software physiology (Zeiss, UK). Mean fluorescence intensity of 8-OHG was 
measured on at least 5 different calibrated images of lung sections of the different groups at 
x40 magnification by using Image J software. An auto threshold for each image was applied 
by using the Huang method in Image J. 
Protein analysis 
Whole lung samples were homogenized and lysed in ice-cold 0.1% lauryl maltoside 
solution in PBS (v/v) and protein concentrations were measured by a BCA assay (Thermo 
Scientific, UK). 30µg of protein was loaded for whole lung homogenates and samples were 
separated by SDS-PAGE. Protein expression of CYP1B1 (2µg/mL; sc-32882, Santa Cruz 
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Biotechnology, USA) and SERT expression (2μg/mL; AB1594P, Millipore, UK) was 
determined by overnight incubation at 4°C and normalized to GAPDH (0.2µg/mL; ab8264, 
Abcam).  
Estrogen immunoassay 
The levels of estrogen were determined by competitive based immunoassay in whole 
lung homogenate samples from female wild-type, SERT+ and SERT+ mice treated with TMS. 
Lung samples were homogenized in ice-cold 1% lauryl maltoside solution in PBS (v/v) and 
solubilized on ice followed by cellular fractionation. Protein concentrations were determined 
by a BCA assay. 400µg of protein was loaded for mouse lung samples and assayed in 
duplicate as per manufacturer’s instructions (Cayman Chemical, Michigan, USA). The plate 
was read at a wavelength of 405nm for end point measurements (SpectraMax M2 plate 
reader, Molecular Devices, California, USA). Data was normalized to per μg of protein. 
Human pulmonary arterial smooth muscle cells 
hPASMCs were provided by Professor Nicholas W. Morrell (University of 
Cambridge). Female hPASMCs were explanted from the distal pulmonary microvasculature 
from subjects with no reported presence of PAH. Three independent female cell lines were 
used in this study and characterized by morphological assessment and staining for the smooth 
muscle cell marker, α-smooth muscle actin. Assays were performed between passages 2 and 
7. Cells were seeded in 24-well plates (cell counts) and 96-well plates (BrdU incorporation) 
at a density of 7500 cells per cm2. Cells were grown to ~60% confluency and then cell-cycle 
synchronized by serum-deprivation (0.2% charcoal-stripped FBS) in phenol-red free DMEM 
(Invitrogen, UK) for 24 hours. 
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Charcoal-stripped fetal bovine serum  
Fetal bovine serum (FBS; Sera Labs, UK) was charcoal stripped twice to remove 
estrogens. Dextran-coated charcoal (Sigma-Aldrich, UK) was added to FBS at a 
concentration of 1g/100mL and left overnight at 4ºC under gentle agitation. Samples were 
centrifuged at 1811g at 4ºC for 30 minutes. The stripped serum was decanted and filtered 
through a 0.22µm filter. ELISA analysis of 50μl of FBS confirmed successful removal of 
estrogen (as described in section above).  
Cell proliferation assays 
hPASMC proliferation was assessed by two approaches; live cell counts (cell 
viability) using a haemocytometer and by a BrdU incorporation assay, as per manufacturers 
protocol (Millipore, UK). Cells were treated for 72 hours, in phenol red free 2% charcoal 
stripped FBS DMEM with 1nM 16α-OHE1, (Steraloids, Inc., USA) and 0.1μM MPP 
Dihydrochloride (ERα antagonist, Tocris, UK) or 0.002pg/mL ERα antibody (sc-7207, Santa 
Cruz Biotechnology, USA). Antagonists/antibodies were added 30 minutes prior to the 
addition of 16α-OHE1. Cell culture media and drugs were replaced after 48 hours and 
PASMC proliferation was assessed at 72 hours. 
Statistics 
Data is represented as the group mean ± SEM. Data was analyzed by either a 
student’s two-tailed t-test or a one-way ANOVA followed by a Tukey’s Post Hoc test. The 
statistical test used is indicated within the figure legends.
This content downloaded from 130.209.115.055 on January 29, 2016 03:15:51 AM
All use subject to University of Chicago Press Terms and Conditions (http://www.journals.uchicago.edu/t-and-c).
11 
 
Results 
Female SERT+ mice develop PH via CYP1B1 
Female mice overexpressing the human SERT develop a spontaneous PH phenotype 
that is dependent on estrogen13. As serotonin can modulate CYP1B1 expression28 and 
CYP1B1 contributes to the development of PH5, we investigated whether the development of 
PH in these mice was related to increased CYP1B1 activity. Overexpression of SERT 
resulted in elevated RVSPs (reflective of PH) compared to wild-type mice and CYP1B1 
inhibition with the highly potent and selective inhibitor TMS attenuated this effect (Fig. 1A). 
As previously reported, female SERT+ mice did not develop RV hypertrophy despite elevated 
RVSPs. This is consistent with observations in numerous transgenic models of PH in 
normoxic conditions12,18,33-35 and no further effects were observed in mice treated with TMS 
(Fig. 1B). Overexpression of SERT and CYP1B1 inhibition had no effect on mean SAPs 
(Fig. S1A). SERT+ mice had lower heart rates compared with wild-type mice and this was 
normalized by CYP1B1 inhibition (Fig. 1C). SERT+ mice had a significant degree of 
pulmonary vascular remodelling within the distal vasculature (where arteries are normally 
composed of a thin vascular layer) and this was attenuated by CYP1B1 inhibition (Fig. 1D). 
CYP1B1 expression was increased in SERT+ mice and CYP1B1 inhibition increased 
estrogen levels in the lung  
Overexpression of the human SERT gene in mice increased CYP1B1 protein 
expression in whole lung homogenates compared with wild-type mice. CYP1B1 expression 
in SERT+ TMS treated mice was not significantly different from wild-type mice, suggesting 
that TMS reduced CYP1B1 expression. These findings were confirmed by 
immunohistochemistry staining for CYP1B1 (Fig. 2A-B).  
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A recent estrogen metabolic analysis of Cyp1b1 knockout mice reported increased 
lung concentrations of estrogen in Cyp1b1 knockout mice compared with wild-type mice36. 
CYP enzymes regulate estrogen metabolism and it is therefore plausible that the increase in 
estrogen concentrations in these mice is attributed to reduced metabolism by CYP1B1. It was 
therefore of interest to assess estrogen concentrations in the lungs of SERT+ mice to 
determine the effect of SERT overexpression and CYP1B1 inhibition. Whole lung estrogen 
concentrations were determined by ELISA and found to be similar in SERT+ mice and wild-
type mice. However, CYP1B1 inhibition in SERT+ mice increased estrogen concentrations 
(Fig. 2C). 
Oxidative stress is increased in SERT+ lungs  
The formation of ROS by the metabolism of estrogen by CYP1B1 has been 
previously described37 and increased oxidative stress may be associated with the 
pathobiology of PAH38. We therefore investigated whether oxidative stress was regulated by 
CYP1B1 activity in our model by immunohistochemical analysis of 8-OHG (a sensitive 
measure of ROS. Female SERT+ mice had increased levels of 8-OHG compared to wild-type 
mice and CYP1B1 inhibition with TMS had no effect on 8-OHG levels (Fig. 3A-B). 8-OHG 
was expressed within numerous cellular compartments in SERT+ mice treated with vehicle 
and TMS, including alveoli, bronchi, bronchioles and vessels, whereas it was visually less in 
control mice (Fig. 3A-B). 8-OHG was observed in both the cytoplasm and the nucleus 
indicating increased RNA and DNA oxidation.  
CYP1B1 inhibition did not improve right ventricular function in MCT-induced PH but 
prolonged survival 
Previous studies have reported increased SERT expression in the MCT model of 
PH29. Because the over-expression of human SERT increased CYP1B1 expression in our 
mouse model, we rationalised that CYP1B1 expression would also be increased by MCT. 
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Whole lung expression of SERT protein was increased in female but not in male rats (Fig. 
4A). However, CYP1B1 protein expression (Fig. 4B) was unchanged in the lungs from both 
male and female rats that had been treated with MCT for 28 days (all tissue examined was 
taken from animals that survived until day 28). MCT induced significant increases in RVSP 
(Fig. 5A) and RV hypertrophy (Fig. 5B). TMS had no effects on RVSP (Fig. 5A) and only 
moderate, yet significant effects in reducing RV hypertrophy in male rats, whilst no effects 
were observed in female rats (Fig. 5B). Male rats developed more severe RV hypertrophy in 
comparison with female rats in response to MCT, despite developing a similar degree of 
increased RVSP (Fig. 5A-B). MCT and TMS treatment had no effects on mean SAPs in 
female and male rats (Fig. S2A). MCT lowered the heart rate in male rats and this was 
normalized by TMS to pressures similar to vehicle-treated rats. No changes in heart rate were 
observed in female rats (Fig. 5C). Mortalities were reported 23 and 26 days after MCT 
administration in male and female rats, respectively. TMS prolonged survival in male rats 
and no mortalities were reported in female rats treated with TMS two weeks after 
administration with MCT (Fig. 5D). MCT induced a significant degree of pulmonary vascular 
remodelling in the distal vasculature and this was not affected by CYP1B1 inhibition (Fig. 
6A-B). CYP1B1 immuno-positive cells were predominantly observed in pulmonary arterial 
endothelial cells (Fig. 6C). 
The CYP1B1 metabolite 16α-OHE1 stimulates PASMC proliferation via ERα  
PASMC proliferation is an established and dominant feature associated with PAH 
pathobiology26,27 and we have previously shown that estrogen induces hPASMC proliferation 
via CYP1B15. Using immunohistochemistry, we determined that both SERT and CYP1B1 
are highly expressed in α-SMA positive cells (PASMCs) in pulmonary arteries from patients 
with PAH, whereas minimal expression is observed in non-PAH arteries (Fig. 7). SERT 
overexpression in mice increased the expression of CYP1B1, suggesting that the PH 
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phenotype observed in these mice may be mediated by increased cellular proliferation. To 
investigate this, we performed immunohistochemistry analysis of the DNA replication 
marker PCNA. PCNA expression was increased in SERT+ and this was attenuated by 
CYP1B1 inhibition (Fig. 8A-B). We next investigated whether the proliferative CYP1B1 
estrogen metabolite 16α-OHE1 promoted proliferation via the estrogen receptor ERα by 
selectively blocking ERα by a specific antagonist and antibody. 16α-OHE1 induced 
significant increases in PASMC proliferation and this was completely attenuated by blocking 
ERα signalling using both a specific antagonist and antibody, as assessed by cell number 
(Fig. 8C, E) and BrdU incorporation (Fig. 8D, F). To prove that these effects were directly 
related to an inhibition of 16α-OHE1 signalling through ERα and not by indirect effects 
mediated by the antagonist or antibody, we stimulated hPASMCs with each treatment alone 
and observed no effects (data not shown).  
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Discussion 
The incidence of PAH is more common in women than in men1-3. For example, in the 
largest PAH registry in the World, the Registry to Evaluate Early and Long-Term PAH 
Disease Management (REVEAL), more than 80% of patients diagnosed were females3. This 
suggests that estrogens and/or its metabolites may be associated with the pathobiology of 
PAH. Understanding the biological basis of this gender disparity may offer a new treatment 
paradigm in this devastating cardiovascular disorder that currently has a high unmet clinical 
need.  
We have previously shown that serotonin can upregulate the expression of CYP1B1 
in hPASMCs13. Accordingly, female mice that overexpress the human SERT gene have 
increased CYP1B1 expression and inhibition of CYP1B1 reduces CYP1B1 expression and 
can attenuate PH in these mice. This is consistent with the literature, where TMS has been 
shown to inhibit CYP1B1 mRNA and protein expression in a concentration-dependent 
manner39. Of note, female SERT+ mice do not develop RV hypertrophy in the face of 
increased RVSP and muscularization of the pulmonary arteries. This is consistent with 
numerous transgenic models where mice develop a spontaneous PH phenotype in normoxic 
conditions12,18,33-35. Although the reasons for this observation in the PH field remains 
undetermined, we speculate that this may be related to an inability of mice to develop 
compensatory RV hypertrophy in the face of moderate PH.  
In the 1980’s there was a PAH epidemic in women that had taken the anorexigens, 
dexfenfluramine and aminorex40,41. Both of these drugs are substrates for SERT and act as 
indirect serotinergic agonists42. This outbreak formulated the ‘serotonin hypothesis of PAH’ 
and suggested a direct interaction between SERT and the development of PAH. More 
recently, we have shown that administration of dexfenfluramine in mice results in the 
development of PH in female mice only and this is dependent on intact ovaries and 
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CYP1B120. These observations suggest that SERT facilitates the development of estrogen-
related PH via CYP1B1. This may be relevant to human PAH as CYP1B1 is both highly up-
regulated in disease5 and polymorphisms of CYP1B1 confer increased susceptibility amongst 
patients with a BMPR2 mutation7. In addition, we recently demonstrated that proliferation of 
female hPASMCs is increased via a reduction in BMPR2 signalling and that the CYP1B1 
metabolite 4-hydroxyestradiol can modulate BMPR2 signalling in a gender specific fashion12.  
Overexpression of SERT increased CYP1B1 expression in vivo and this was 
accompanied by increased expression of the proliferative marker PCNA. Inhibition of 
CYP1B1 in SERT+ mice reduced CYP1B1 and PCNA expression in the pulmonary arteries 
and the degree of pulmonary vascular remodelling. Estrogen promotes proliferation of 
hPASMCs5,13 and CYP1B1 inhibition can attenuate this effect in a dose-dependent fashion5. 
Proliferative screens of the most prominent CYP1B1 metabolites of estrogen revealed that the 
16α-hydroxylated estrogens promote PASMC proliferation5. Inhibition of estrogen synthesis 
and its receptor ERα can attenuate experimental PH in female rodents6,43. ERα is 
predominantly regarded as a nuclear receptor, but its expression may also be observed at the 
cell membrane. Upon ligand binding, the nuclear receptor dimerises and translocates to the 
nucleus where it acts as a regulator of gene transcription. Previous studies have shown that 
BMPR2 mutant pulmonary microvascular endothelial cells signal through non-canonical 
pathways by reduced trafficking of ERα to the cell nucleus8. Furthermore, ERα can suppress 
the transcriptional activation of the BMPR2 gene by binding to a conserved estrogen 
response element within its promoter8. Here, we show that ERα mediates the proliferative 
effects of the CYP1B1 metabolite 16α-OHE1. This is of interest as the concentrations of 16α-
OHE1 are elevated in the urine of mice exposed to hypoxia5, BMPR2 mutant mice9 and 
importantly also in patients with PAH7. We rationalized to focus our studies on ERα given its 
more prominent role in the pathobiology of PAH6,8,43,44. However it should be noted that 16α-
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OHE1 has a high binding affinity for ERβ45 and may therefore also be signalling through this 
receptor.  
The role for estrogen in the pathobiology of PAH has been met with much speculation 
and controversial data. Indeed numerous pre-clinical studies have reported compelling 
evidence that estrogen mediates protective effects in the cardiopulmonary unit13,14,46,47. 
Estrogen is a potent vasodilator in the pulmonary vascular bed48 and physiological increases 
in circulating estrogens (the estrous cycle) can attenuate pulmonary arterial vasoconstriction 
under both normoxic and hypoxic conditions49. On the contrary, endogenous synthesis of 
estrogen contributes to the development of PH and associated RV hypertrophy in intact 
female rodents6. Moreover, there is a positive correlation between circulating estrogen levels 
and the degree of RV hypertrophy suggesting an association between estrogens and disease 
severity6. The estrogen synthesizing enzyme aromatase is expressed within the smooth 
muscle cell layer of the pulmonary arterial wall6, suggesting that estrogens can be produced 
locally. Local estrogens would be predicted to have a much more profound effect than the 
impact of the relatively low concentrations circulating in the blood stream17. Here, we show 
that CYP1B1 inhibition increases estrogen concentrations in the lung, which is consistent 
with a previous study in Cyp1b1 knockout mice36. This suggests that the pathobiology behind 
estrogen-associated PAH may be, at least in part, mediated by its downstream metabolism. 
Increasing evidence suggests that altered redox signaling may be associated with the 
pathobiology of PAH and elevated ROS has been observed in numerous animal models and 
in patients with PAH50. Estrogen metabolism by CYP1B1 to the 4-hydroxylated estrogens is 
associated with the formation of ROS which can generate quinones and semi-quinones that 
can mediate DNA damage by the formation of DNA adducts51,52. We had therefore 
anticipated that CYP1B1 inhibition might alleviate oxidative stress. Although we observed 
increased ROS expression in SERT+ mouse lungs, this was unaffected by CYP1B1 inhibition, 
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suggesting that other pathways unrelated to CYP1B1 activity contribute to the elevated 
oxidative stress in SERT+ mice.  
The MCT rat model has been and continues to be used as a model of PH despite 
having received criticism as a pre-clinical model of PAH53. However, previous studies have 
shown that MCT increases lung expression of SERT and that inhibition of SERT can prevent 
the development of MCT-induced PH29. We therefore questioned whether this was related to 
elevated CYP1B1 activity and hypothesized that CYP1B1 inhibition may be effective in 
reversing MCT-induced PH. Although we observed an increase in SERT expression in 
female rats, this was not accompanied by an increase in CYP1B1 expression. This is likely 
due to the relatively moderate increase of SERT expression in comparison to the mouse 
model overexpressing SERT. The lack of increased CYP1B1 expression and the different 
cellular localization compared with mouse and humans (endothelial vs. smooth muscle cell) 
may underlie the relatively mild therapeutic effects observed. In male rats, CYP1B1 
inhibition reduced RV hypertrophy and improved survival. In female rats, no effect was 
reported on PH indices, yet a small improvement in survival was observed. Clinically, 
survival in males with PH is worse than in females and this is thought to be related to a worse 
RV function54 and indeed, RV function is a strong predictor of survival55. In this study, the 
degree of RV hypertrophy was more profound in male rats treated with MCT compared with 
females and this was associated with poorer survival. MCT is bioactivated by CYPs to its 
active compound MCT pyrrole in the liver. Sex-specific CYPs may regulate MCT 
metabolism in the liver and underlie the gender difference in response to MCT. Of interest, 
the exogenous administration of estrogen has been shown to be therapeutic in MCT-treated 
rats by activation of ERβ16. This may explain the reduced degree of RV hypertrophy and the 
increased survival in female rats compared with male rats. However, we have recently 
reported pathogenic effects of endogenous estrogens in females in other models of PH6. The 
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influence of estrogens on RV function is still controversial in the literature. In healthy 
females on hormone replacement therapy, increased estrogen levels correlated with an 
improved RV function56. However, recently it has been show that men with idiopathic PAH 
have elevated estrogen levels and this is correlated with a poorer RV function and six minute 
walking test57.  
Serotonin and SERT are mediators in the pathogenesis of PAH. Over-activity of the 
estrogen and serotonergic pathways may be associated with the development of PAH, 
particularly in women, by increasing CYP1B1 expression promoting pro-proliferative 
estrogen metabolism. Targeting CYP1B1 is currently being explored therapeutically in 
clinical trials in cancer patients, using a vaccination with a DNA plasmid encoding an 
inactivated form of CYP1B1 (ZYC300). Upon delivery, the immune system elicits a 
cytotoxic T lymphocyte mediated-response against CYP1B1 resulting in the lysis of CYP1B1 
expressing cells58,59. This may be a strong therapeutic candidate in female patients that have 
elevated CYP1B1 expression. The subset of patients that would respond to this therapy could 
be identified by measuring the urinary 2-OHE1/16α-OHE1 ratio, as previously reported7. 
Current PAH therapies do not encompass this well-defined gender disparity that occurs in 
PAH, or the potential divergent response to current therapies that may be affected by gender. 
Future therapies that target dysregulated estrogen metabolism may have a favourable 
outcome in this highly neglected, devastating cardiovascular disease. 
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Figure Legends 
Figure 1. Inhibition of CYP1B1 with 2,3',4,5'-tetramethoxystilbene (TMS) attenuates 
PH in female SERT+ mice. 
Female SERT+ mice were injected with 1.5mg/kg i.p. TMS for two-weeks and compared 
with wild-type (C57Bl/6J CBA) and SERT+ vehicle treated mice for its effects on PH indices. 
(A) RVSP measurement per group as measured by transdiaphragmatic puncture; n=9-10 (B) 
Right ventricular hypertrophy expressed as the ratio of the weight of the right ventricle (RV) 
over the left ventricle + septum (LV+S); n=10-11. (C) Heart rate; n=7-9. (D) Pulmonary 
vascular remodeling; n=5-6. (E) Representative images of pulmonary vascular remodeling in 
arteries for each group. Scale bar = 20μm. Data was analyzed by a one-way ANOVA 
followed by a Tukey’s post-hoc test. *P<0.05, **P<0.01, ***P<0.001. 
Figure 2. CYP1B1 expression is increased in female SERT+ mice and CYP1B1 
inhibition increases estrogen concentrations in lung homogenates. 
Female SERT+ mice were injected with 1.5mg/kg i.p. 2,3',4,5'-tetramethoxystilbene (TMS) 
for two-weeks and compared with wild-type (C57Bl/6J CBA) and SERT+ vehicle treated 
mice. (A) Whole lung homogenates (30μg) were analyzed for CYP1B1 expression by 
western blotting and normalized to GAPDH, n=5-8. (B) Representative CYP1B1 
immunolocalization in pulmonary arteries as determined by VIP positive cells (pink). Scale 
bar = 20μm. (C) Estrogen concentrations as determined by ELISA in 400μg of whole lung 
homogenates; n=4-5. Data was analyzed by a one-way ANOVA followed by a Tukey’s post-
hoc test. ***P<0.001. 
Figure 3. SERT+ mice have increased RNA and DNA oxidative damage in the lungs. 
(A) Lung sections obtained from wild-type, SERT+ and SERT+ mice treated with the 
CYP1B1 inhibitor 2,3',4,5'-tetramethoxystilbene (TMS) were immunostained for the 
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oxidative stress marker 8-hydroxyguanosine (8-OHG). Sections were counterstained with the 
nuclear stain, DAPI. Scale bar = 50μm. (B) 8-OHG mean fluorescence intensity was 
measured in whole lung sections using Image J software analysis; n=4-5. Data was analyzed 
by a one-way ANOVA followed by a Tukey’s post-hoc test. *P<0.05, **P<0.01. 
Figure 4. SERT and CYP1B1 expression in monocrotaline (MCT) treated rats 
Female and male rats were given a single dose of MCT (60mg/kg s.c.) and 28 days later 
whole lung homogenates were analysed for protein expression by western blotting for (A) 
SERT, n=6 and (B) CYP1B1, n=8. Data was normalised to GAPDH. Data was analyzed by 
an unpaired t-test. *P<0.05.   
Figure 5. Inhibition of CYP1B1 with 2,3',4,5'-tetramethoxystilbene (TMS) does not 
reverse monocrotaline (MCT)-induced PH yet improves survival. 
Female and male rats were given a single dose of MCT (60mg/kg s.c.) and 14 days later were 
given TMS (3mg/kg/day i.p.) or vehicle (~5% ethanol in saline) for an additional 14 days and 
then assessed for indices of PH. (A) Right ventricular systolic pressures (RVSP) as assessed 
by jugular vein cannulation; n=5-11. (B) Right ventricular hypertrophy as assessed by the 
weight of the right ventricle (RV) over the left ventricle + septum (LV+S); n=9-14. (C) Heart 
rate; n=6-12. (D) Kaplan Meier survival analysis in rats treated with MCT (total of 16 
animals per group at the start of the experiment). Data was analyzed by a one-way ANOVA 
followed by a Tukey’s post-hoc test. *P<0.05, **P<0.01, ***P<0.001 vehicle vs. MCT; 
#P<0.05 male vs. female. 
Figure 6. Inhibition of CYP1B1 with 2,3',4,5'-tetramethoxystilbene (TMS) does not 
reverse monocrotaline (MCT)-induced pulmonary arterial remodelling 
Female and male rats were given a single dose of MCT (60mg/kg s.c.) and 14 days later were 
given TMS (3mg/kg/day i.p.) or vehicle (~5% ethanol in saline) for an additional 14 days and 
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then assessed for indices of PH. (A) Pulmonary vascular remodeling; n=6-7. Data was 
analyzed by a one-way ANOVA followed by a Tukey’s post-hoc test. **P<0.01, 
***P<0.001. (B) Representative pulmonary arteries for each group. Scale bar = 20μm. (C) 
CYP1B1 immunolocalization in representative pulmonary arteries indicates positive cells in 
the endothelial cell layer and peri-adventitial layer as visualised by DAB (dark brown). 
Sections were counterstained with haematoxylin. Scale bar = 50μm. 
Figure 7. SERT and CYP1B1 are expressed in α-smooth muscle actin positive cells in 
human pulmonary arteries 
Immunolocalization of SERT, CYP1B1 and α-smooth muscle actin (α-SMA) in human 
pulmonary arteries of non-PAH and PAH lung sections as visualised by DAB (dark brown). 
Lung samples were from a female age 26 with heritable PAH and a female age 51 with 
idiopathic PAH. Scale bar = 200μm. 
Figure 8. The CYP1B1 metabolite 16α-hydroxyestrone (16α-OHE1) induces cell 
proliferation via estrogen receptor α (ERα).  
(A) Representative images of immunohistochemistry analysis of the DNA replication marker, 
PCNA in wild-type, SERT+ mice treated with vehicle and the CYP1B1 inhibitor, 2,3',4,5'-
tetramethoxystilbene TMS. Scale bar = 20μm. (B) Percentage PCNA positive nuclei. n=3-6; 
3-4 pulmonary arteries analyzed per lung. Data was analyzed by a one-way ANOVA 
followed by a Tukey’s post hoc test . ***P<0.001. Female human pulmonary arterial smooth 
muscle cells (PASMCs) were incubated with 16α-OHE1 for 72 hours in 2% charcoal stripped 
serum in the presence or absence of ERα inhibition and assessed for proliferation by cell 
counts and BrdU incorporation. 16α-OHE1 induced PASMC proliferation in the presence of 
a selective ERα antagonist MPP dihydrochloride (0.1μM) as assessed by (C) cell counts; 
n=15 replicates per group (D) and BrdU incorporation; n=11 replicates per group. 16α-OHE1 
induced PASMC proliferation in the presence of a specific ERα antibody (0.002pg/mL) as 
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assessed by (E) cell counts; n=6-9 replicates per group and (F) BrdU incorporation; n=16 
replicates per group. Data was analyzed by a one-way ANOVA followed by a Tukey’s post 
hoc test. **P<0.01, ***P<0.001. 
Figure S1. Inhibition of CYP1B1 with 2,3',4,5'-tetramethoxystilbene (TMS) has no 
effects on mean systemic arterial pressures (SAP). 
Female SERT+ mice were injected with 1.5mg/kg i.p. TMS for two-weeks and compared 
with wild-type (C57Bl/6J CBA) and SERT+ vehicle treated mice. Mean SAPs were measured 
by cannulation of the carotid artery; n=7-10. Data was analyzed by a one-way ANOVA 
followed by a Tukey’s post-hoc test. 
Figure S2. Inhibition of CYP1B1 with 2,3',4,5'-tetramethoxystilbene (TMS) and 
monocrotaline (MCT) has no effects on mean systemic arterial pressures (SAP). 
Female and male rats were given a single dose of MCT (60mg/kg s.c.) and 14 days later were 
given TMS (3mg/kg/day i.p.) or vehicle (~5% ethanol in saline) for an additional 14 days. 
Mean SAPs were measured by cannulation of the carotid artery; n=5-11. Data was analyzed 
by a one-way ANOVA followed by a Tukey’s post-hoc test.
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